Table 1

Patients’ characteristics at diagnosis and during follow-up

CharacteristicNo. evaluableNo. of patients%95% CI
At diagnosis     
 Age, years 1545    
  Median  61  
  Range  18-95  
 Sex 1545    
  Male  760 49  
  Female  785 51  
 Hemoglobin, g/dL 1545    
  Median  18.4  
  Range  15.1-26.5  
 Hematocrit, % 1545    
  Median  55  
  Range  36-78  
 Leukocyte count, × 109/L 1545    
  Median  10.4  
  Range  3-171.6  
 Platelet count, × 109/L 1545    
  Median  466  
  Range  7-2370  
 JAK2V617F mutation 1268 1239 98  
 Pruritus 1349 485 36  
 Vasomotor symptoms 1412 403 29  
 Palpable spleen 1477 534 36  
 History of tobacco use 1301 206 16  
 History of diabetes 1149 97 8  
 History of hyperlipidemia 1073 196 18  
 History of hypertension 1388 638 46  
 Leukoerythroblastic smear 1056 63 6  
 Abnormal karyotype 631 77 12  
 Arterial thrombosis before/at diagnosis 1545 246 16  
   Acute myocardial infarction 1545 65 4  
  Stroke/transient ischemic attack 1545 138 9  
  Peripheral arterial thrombosis 1545 29 2  
  Other/unknown 1545 14 1  
 Venous thrombosis before/at diagnosis 1545 114 7  
   Deep vein thrombosis/pulmonary embolism 1545 78 5  
  Splanchnic thrombosis 1545 30 2  
  Other/unknown 1545 6 0  
 Major hemorrhage before/at diagnosis 572 24 4  
Follow-up     
 Years of follow-up 1545    
  Median  6.9  
  Range  0-39  
 Treatments     
  Cytoreductive therapy* 1545 1129 73  
  Aspirin therapy 1535 1281 84  
 Total thrombosis 1545 290 19  
  Incidence rate, % patients per year   2.62 2.34-2.94 
 Arterial thrombosis 1545 184 12  
  Incidence rate, % patients per year  1.59 1.38-1.84 
  Acute myocardial infarction 1545 35 2  
  Stroke/transient ischemic attack 1545 104 7  
  Peripheral arterial thrombosis 1545 34 2  
  Other/unknown 1545 11 1  
 Venous thrombosis 1545 137 9  
  Incidence rate, % patients per year   1.05 0.88-1.25 
   Deep vein thrombosis/pulmonary embolism 1545 88 6  
  Splanchnic thrombosis 1545 27 2  
  Other/unknown 1545 22 1  
 Fatal cardiovascular events 1545 51 15  
 Myelofibrosis/acute myeloid leukemia transformations 1545 174 11  
  Incidence rate, % patients per year   1.42 1.22-1.65 
 Death 1545 347 23  
  Incidence rate, % patients per year   2.74 2.46-3.04 
CharacteristicNo. evaluableNo. of patients%95% CI
At diagnosis     
 Age, years 1545    
  Median  61  
  Range  18-95  
 Sex 1545    
  Male  760 49  
  Female  785 51  
 Hemoglobin, g/dL 1545    
  Median  18.4  
  Range  15.1-26.5  
 Hematocrit, % 1545    
  Median  55  
  Range  36-78  
 Leukocyte count, × 109/L 1545    
  Median  10.4  
  Range  3-171.6  
 Platelet count, × 109/L 1545    
  Median  466  
  Range  7-2370  
 JAK2V617F mutation 1268 1239 98  
 Pruritus 1349 485 36  
 Vasomotor symptoms 1412 403 29  
 Palpable spleen 1477 534 36  
 History of tobacco use 1301 206 16  
 History of diabetes 1149 97 8  
 History of hyperlipidemia 1073 196 18  
 History of hypertension 1388 638 46  
 Leukoerythroblastic smear 1056 63 6  
 Abnormal karyotype 631 77 12  
 Arterial thrombosis before/at diagnosis 1545 246 16  
   Acute myocardial infarction 1545 65 4  
  Stroke/transient ischemic attack 1545 138 9  
  Peripheral arterial thrombosis 1545 29 2  
  Other/unknown 1545 14 1  
 Venous thrombosis before/at diagnosis 1545 114 7  
   Deep vein thrombosis/pulmonary embolism 1545 78 5  
  Splanchnic thrombosis 1545 30 2  
  Other/unknown 1545 6 0  
 Major hemorrhage before/at diagnosis 572 24 4  
Follow-up     
 Years of follow-up 1545    
  Median  6.9  
  Range  0-39  
 Treatments     
  Cytoreductive therapy* 1545 1129 73  
  Aspirin therapy 1535 1281 84  
 Total thrombosis 1545 290 19  
  Incidence rate, % patients per year   2.62 2.34-2.94 
 Arterial thrombosis 1545 184 12  
  Incidence rate, % patients per year  1.59 1.38-1.84 
  Acute myocardial infarction 1545 35 2  
  Stroke/transient ischemic attack 1545 104 7  
  Peripheral arterial thrombosis 1545 34 2  
  Other/unknown 1545 11 1  
 Venous thrombosis 1545 137 9  
  Incidence rate, % patients per year   1.05 0.88-1.25 
   Deep vein thrombosis/pulmonary embolism 1545 88 6  
  Splanchnic thrombosis 1545 27 2  
  Other/unknown 1545 22 1  
 Fatal cardiovascular events 1545 51 15  
 Myelofibrosis/acute myeloid leukemia transformations 1545 174 11  
  Incidence rate, % patients per year   1.42 1.22-1.65 
 Death 1545 347 23  
  Incidence rate, % patients per year   2.74 2.46-3.04 

CI, confidence interval.

*

Cytoreductive treatments included hydroxyurea, interferon, busulfan, pipobroman, 32P, anagrelide.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal